Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius Sells 2,128 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) SVP Mark Brosius sold 2,128 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total transaction of $1,095,920.00. Following the sale, the senior vice president now directly owns 273 shares of the company’s stock, valued at approximately $140,595. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Brosius also recently made the following trade(s):

• On Thursday, October 24th, Mark Brosius sold 22 shares of Intuitive Surgical stock. The shares were sold at an average price of $510.79, for a total transaction of $11,237.38.
• On Thursday, September 12th, Mark Brosius sold 2,115 shares of Intuitive Surgical stock. The shares were sold at an average price of $491.91, for a total transaction of $1,040,389.65.

Intuitive Surgical Trading Down 0.2 %

NASDAQ:ISRG opened at $511.63 on Friday. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $523.34. The company has a market cap of $181.48 billion, a price-to-earnings ratio of 92.35, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The stock has a fifty day simple moving average of $486.71 and a 200-day simple moving average of $440.96.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ISRG shares. Piper Sandler reissued an “overweight” rating and issued a $538.00 target price (up from $495.00) on shares of Intuitive Surgical in a report on Friday, October 18th. Leerink Partners raised their target price on shares of Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. BTIG Research set a $535.00 target price on shares of Intuitive Surgical in a report on Friday, October 18th. Royal Bank of Canada raised their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a report on Friday, October 18th. Finally, Oppenheimer reissued a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Institutional Trading of Intuitive Surgical

Institutional investors and hedge funds have recently made changes to their positions in the business. Creekmur Asset Management LLC lifted its position in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 42 shares during the last quarter. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical in the second quarter valued at about $26,000. Delos Wealth Advisors LLC raised its holdings in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares in the last quarter. Godsey & Gibb Inc. raised its holdings in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 35 shares in the last quarter. Finally, LRI Investments LLC bought a new stake in shares of Intuitive Surgical in the first quarter valued at about $30,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.